| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & Head of R& D | CMO & Head of R& D
2 companies
Christopher Cabell is President & Head of R& D at IKT and has filed Form 4s across 2 companies. Christopher Cabell's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.6M at current prices.
The biggest single holding is IKT (~$1.0M) as President & Head of R& D.
Christopher Cabell has 8 Form 4 filings on record from June 2020 to February 2026, across 3 companies: President & Head of R & D at Inhibikase Therapeutics (IKT), 2025–2026; CMO & Head of R & D at Zura Bio (ZURA), 2023; Director at Pulmatrix (PULM), 2020–2023.
The 8 reported transactions were 6 option or other derivative awards, 1 disposition back to the company and 1 stock award.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria